Affimed Logo.jpg
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
May 23, 2024 17:05 ET | Affimed N.V.
In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led...
Affimed Logo.jpg
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
April 24, 2024 04:05 ET | Affimed N.V.
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been...
Affimed Logo.jpg
Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 05, 2022 08:05 ET | Affimed N.V.
A poster evaluating comprehensive correlative science findings from the AFM24 monotherapy phase 1 study (AFM24-101) will be presentedIn a second poster presentation, initial phase 1 dose escalation...